{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:20:39Z","timestamp":1792182039251,"version":"4.4.0"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>Liver transplantation (LT) is the treatment of choice for patients with hepatocellular carcinoma (HCC). Recurrence of HCC after LT occurs in 10% to 20% of cases. Preclinical studies to evaluate immune checkpoint inhibitors in conjunction with immunosuppressant treatment in transplant recipients have been lacking. Here, we evaluated the efficacy, safety, and mechanism of programmed cell death-1 (PD1) blockade under tacrolimus treatment in transplant recipients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>We used a murine allogeneic skin transplantation model and murine syngeneic subcutaneous and orthotopic HCC models and measured the tumor volume and the change in tumor-infiltrating lymphocytes under PD1 blockade and tacrolimus treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>Tacrolimus treatment prolonged allograft survival in the allogeneic transplantation model and enhanced tumor growth in both subcutaneous and orthotopic HCC models. PD1 blockade suppressed tumor growth and lung metastasis in correlation with the number of infiltrating CD8<jats:sup>+<\/jats:sup> T cells. Under tacrolimus treatment, PD1 blockade still resulted in an antitumor effect accompanied by a significant increase in tumor-infiltrating CD8<jats:sup>+<\/jats:sup> T cells, natural killer cells, dendritic cells, and natural killer T cells. Tacrolimus treatment rescued the acceleration of transplant rejection induced by PD1 blockade in the allogeneic transplantation model.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>Our data suggest that treatment with high-dose tacrolimus in conjunction with PD1 blockade has an antitumor effect and reduces transplant rejection in mouse models of allograft skin transplantation and HCC. Thus, these results suggest that a clinical trial of PD1 inhibitors for HCC in LT merits consideration.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/tp.0000000000004425","type":"journal-article","created":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T05:00:25Z","timestamp":1668574825000},"page":"1492-1501","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":14,"title":["Therapeutic Effects of Anti-PD1 Immunotherapy on Hepatocellular Carcinoma Under Administration of Tacrolimus"],"prefix":"10.1097","volume":"107","author":[{"given":"Yu-Chen","family":"Hsu","sequence":"first","affiliation":[{"name":"Liver Disease Prevention and Treatment Research Foundation, Taiwan, Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Hung","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medicine, National Taiwan University Cancer Center, Taipei, Taiwan, Republic of China."},{"name":"Department of Internal Medicine, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan, Republic of China."},{"name":"Department of Internal Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan, Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Fu","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Surgery, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan, Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Te","family":"Lee","sequence":"additional","affiliation":[{"name":"Liver Disease Prevention and Treatment Research Foundation, Taiwan, Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Chuan","family":"Wu","sequence":"additional","affiliation":[{"name":"Liver Disease Prevention and Treatment Research Foundation, Taiwan, Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Wen","family":"Su","sequence":"additional","affiliation":[{"name":"Liver Disease Prevention and Treatment Research Foundation, Taiwan, Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huei-Chi","family":"Chou","sequence":"additional","affiliation":[{"name":"Liver Disease Prevention and Treatment Research Foundation, Taiwan, Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Fang","family":"Wang","sequence":"additional","affiliation":[{"name":"Liver Disease Prevention and Treatment Research Foundation, Taiwan, Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsuan-Shu","family":"Lee","sequence":"additional","affiliation":[{"name":"Liver Disease Prevention and Treatment Research Foundation, Taiwan, Republic of China."},{"name":"Department of Internal Medicine, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan, Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Wha","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, Taiwan, Republic of China."},{"name":"Department of Laboratory Medicine, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan, Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping-Ning","family":"Hsu","sequence":"additional","affiliation":[{"name":"Graduate Institute of Immunology, College of Medicine, National Taiwan University, Taipei, Taiwan, Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao-Ming","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Surgery, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan, Republic of China."},{"name":"Department of Surgery, College of Medicine, National Taiwan University, Taipei, Taiwan, Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Chuan","family":"Sheu","sequence":"additional","affiliation":[{"name":"Liver Disease Prevention and Treatment Research Foundation, Taiwan, Republic of China."},{"name":"Department of Internal Medicine, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan, Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Tzu","family":"Weng","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan, Republic of China."},{"name":"Department of Medical Research, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan, Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,6,20]]},"reference":[{"key":"R1-20250604","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1097\/TP.0000000000002987","article-title":"Posttransplant calcineurin inhibitors levels and intrapatient variability are not associated with long-term outcomes following liver transplantation.","volume":"104","author":"Di Maira","year":"2020","journal-title":"Transplantation"},{"key":"R2-20250604","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/TP.0000000000002532","article-title":"Asian liver transplant network clinical guidelines on immunosuppression in liver transplantation.","volume":"103","author":"Tan","year":"2019","journal-title":"Transplantation"},{"issue":"2S Suppl 1","key":"R3-20250604","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1097\/TP.0000000000001690","article-title":"mTOR inhibition and clinical transplantation: liver.","volume":"102","author":"Nashan","year":"2018","journal-title":"Transplantation"},{"key":"R4-20250604","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1097\/TP.0000000000002647","article-title":"Suppression of hepatocellular carcinoma by mycophenolic acid in experimental models and in patients.","volume":"103","author":"Chen","year":"2019","journal-title":"Transplantation"},{"key":"R5-20250604","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/lt.24742","article-title":"Recurrence of hepatocellular carcinoma after liver transplantation: is there a place for resection?","volume":"23","author":"Fernandez-Sevilla","year":"2017","journal-title":"Liver Transpl"},{"key":"R6-20250604","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1097\/TP.0000000000003434","article-title":"Early versus late hepatocellular carcinoma recurrence after transplantation: predictive factors, patterns, and long-term outcome.","volume":"105","author":"El-Domiaty","year":"2021","journal-title":"Transplantation"},{"key":"R7-20250604","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma.","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"R8-20250604","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.1097\/TP.0000000000003228","article-title":"Sorafenib for hepatocellular carcinoma recurrence after liver transplant.","volume":"104","author":"Mancuso","year":"2020","journal-title":"Transplantation"},{"key":"R9-20250604","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"R10-20250604","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol"},{"key":"R11-20250604","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"R12-20250604","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1177\/2050640618774631","article-title":"Use of checkpoint inhibitors in liver transplant recipients.","volume":"6","author":"Munker","year":"2018","journal-title":"United European Gastroenterol J"},{"key":"R13-20250604","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.21037\/jgo.2018.07.05","article-title":"Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience.","volume":"9","author":"DeLeon","year":"2018","journal-title":"J Gastro Oncol"},{"key":"R14-20250604","first-page":"e11150","article-title":"Anti-programmed cell death protein 1 (PD-1) immunotherapy for metastatic hepatocellular carcinoma after liver transplantation: a report of three cases.","volume":"12","author":"Al Jarroudi","year":"2020","journal-title":"Cureus"},{"key":"R15-20250604","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jceh.2019.11.009","article-title":"Successful treatment of disseminated hepatocellular carcinoma after liver transplantation with nivolumab.","volume":"10","author":"Amjad","year":"2020","journal-title":"J Clin Exp Hepatol"},{"key":"R16-20250604","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/TP.0000000000002768","article-title":"Impact of induction immunosuppression strategies in simultaneous liver\/kidney transplantation.","volume":"104","author":"Kamal","year":"2020","journal-title":"Transplantation"},{"key":"R17-20250604","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1097\/TP.0000000000002700","article-title":"Improved survival in liver transplant patients receiving prolonged-release tacrolimus-based immunosuppression in the European Liver Transplant Registry (ELTR): an extension study.","volume":"103","author":"Adam","year":"2019","journal-title":"Transplantation"},{"key":"R18-20250604","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/00007890-199808270-00014","article-title":"A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: a report of the United States FK506 Study Group.","volume":"66","author":"Wiesner","year":"1998","journal-title":"Transplantation"},{"key":"R19-20250604","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep27915","article-title":"Calcineurin inhibitors cyclosporine A and tacrolimus induce vascular inflammation and endothelial activation through TLR4 signaling.","volume":"6","author":"Rodrigues-Diez","year":"2016","journal-title":"Sci Rep"},{"key":"R20-20250604","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/hepr.12789","article-title":"Programmed cell death-1 blockade enhances response to stereotactic radiation in an orthotopic murine model of hepatocellular carcinoma.","volume":"47","author":"Friedman","year":"2017","journal-title":"Hepatol Res"},{"key":"R21-20250604","first-page":"7563","article-title":"Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma.","volume":"61","author":"Tatsumi","year":"2001","journal-title":"Cancer Res"},{"key":"R22-20250604","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1158\/0008-5472.1089.65.3","article-title":"Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity.","volume":"65","author":"Hirano","year":"2005","journal-title":"Cancer Res"},{"key":"R23-20250604","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/hep.27665","article-title":"CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.","volume":"61","author":"Chen","year":"2015","journal-title":"Hepatology"},{"key":"R24-20250604","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1055\/s-2007-979471","article-title":"The liver: a special case in transplantation tolerance.","volume":"27","author":"Benseler","year":"2007","journal-title":"Semin Liver Dis"},{"key":"R25-20250604","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1001\/jama.2011.1592","article-title":"Spectrum of cancer risk among US solid organ transplant recipients.","volume":"306","author":"Engels","year":"2011","journal-title":"JAMA"},{"key":"R26-20250604","doi-asserted-by":"crossref","first-page":"183523","DOI":"10.1155\/2015\/183523","article-title":"Immunosuppression and multiple primary malignancies in kidney-transplanted patients: a single-institute study.","volume":"2015","author":"Santangelo","year":"2015","journal-title":"Biomed Res Int"},{"key":"R27-20250604","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1097\/TP.0000000000003196","article-title":"Posttransplant management of recipients undergoing liver transplantation for hepatocellular carcinoma. Working group report from the ILTS Transplant Oncology Consensus Conference.","volume":"104","author":"Berenguer","year":"2020","journal-title":"Transplantation"},{"key":"R28-20250604","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1097\/TP.0000000000003997","article-title":"Evaluation and management of liver transplant candidates with prior nonhepatic cancer: guidelines from the ILTS\/SETH consensus conference.","volume":"106","author":"Salcedo","year":"2022","journal-title":"Transplantation"},{"key":"R29-20250604","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1038\/sj.bjc.6694369","article-title":"The role of endotoxin\/lipopolysaccharide in surgically induced tumour growth in a murine model of metastatic disease.","volume":"81","author":"Pidgeon","year":"1999","journal-title":"Brit J Cancer"},{"key":"R30-20250604","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-016-0623-5","article-title":"Cancer immunotherapy: the beginning of the end of cancer?","volume":"14","author":"Farkona","year":"2016","journal-title":"BMC Med"},{"key":"R31-20250604","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/ndt\/gfg594","article-title":"In vitro treatment of dendritic cells with tacrolimus: impaired T-cell activation and IP-10 expression.","volume":"19","author":"Tiefenthaler","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"R32-20250604","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jconrel.2019.11.001","article-title":"Inflammation-triggered local drug release ameliorates colitis by inhibiting dendritic cell migration and Th1\/Th17 differentiation.","volume":"316","author":"Regmi","year":"2019","journal-title":"J Control Release"},{"key":"R33-20250604","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/01.tp.0000296817.28053.7b","article-title":"Rapamycin, but not cyclosporine or FK506, alters natural killer cell function.","volume":"85","author":"Wai","year":"2008","journal-title":"Transplantation"},{"key":"R34-20250604","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3389\/fimmu.2019.00556","article-title":"Small-molecule immunosuppressive drugs and therapeutic immunoglobulins differentially inhibit NK cell effector functions in vitro.","volume":"10","author":"Pradier","year":"2019","journal-title":"Front Immunol"},{"key":"R35-20250604","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/978-981-15-3266-5_3","article-title":"Roles of PD-1\/PD-L1 pathway: signaling, cancer, and beyond.","volume":"1248","author":"Ai","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"R36-20250604","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway.","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"R37-20250604","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41586-020-2015-4","article-title":"ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity.","volume":"579","author":"Moral","year":"2020","journal-title":"Nature"},{"key":"R38-20250604","article-title":"Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients.","author":"Kasanen","journal-title":"Cancer Immunol Immunother"},{"key":"R39-20250604","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.immuni.2007.05.016","article-title":"Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.","volume":"27","author":"Butte","year":"2007","journal-title":"Immunity"},{"key":"R40-20250604","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.4049\/jimmunol.1100056","article-title":"The novel costimulatory programmed death ligand 1\/B7.1 pathway is functional in inhibiting alloimmune responses in vivo.","volume":"187","author":"Yang","year":"2011","journal-title":"J Immunol"},{"key":"R41-20250604","doi-asserted-by":"crossref","first-page":"e0184254","DOI":"10.1371\/journal.pone.0184254","article-title":"PD-1 and CTLA-4 up regulation on donor T cells is insufficient to prevent GvHD in allo-HSCT recipients.","volume":"12","author":"Hossain","year":"2017","journal-title":"PLoS One"},{"key":"R42-20250604","doi-asserted-by":"crossref","first-page":"20406223221099334","DOI":"10.1177\/20406223221099334","article-title":"An analysis report on the application of immune checkpoint inhibitors after liver transplantation.","volume":"13","author":"Xie","year":"2022","journal-title":"Ther Adv Chronic Dis"},{"key":"R43-20250604","first-page":"1","article-title":"Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature.","volume":"7","author":"Abdel-Wahab","year":"2019","journal-title":"J ImmunoTher Cancer"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000004425","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T18:07:35Z","timestamp":1749060455000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000004425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,20]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000004425","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,20]]}}}